Mabion delays profitability target to beyond 2026 on weak 2026 revenue

Polish biotech Mabion says 2026 revenues will fall short of the level needed to hit its profitability threshold in 2026, pushing the target out. The company cites lower-than-expected revenue, though specific figures are not provided. This signals a downward revision to near-term earnings expectations for the firm.